The UK pharmaceutical sector is key in delivering innovations that benefit society whilst also making a significant contribution to the UK economy and knowledge base.  Notwithstanding advances in cell, gene and antibody technologies, small molecule therapies are and will continue to play a vital part in treating patients for the foreseeable future.

We work with a range of companies, start-ups, researchers, manufacturers and providers to offer a broad expertise across regulation, intellectual property, M&A and commercial matters relating to pharmaceuticals.

Our experience includes the following:

  • Acting for a UK based pharmaceutical company in relation to the acquisition of a drug research, development and licensing business with a large portfolio of on-going research projects, IP and product dossiers
  • Acting for a consortium looking to develop and exploit a new test for a disease, including advising on patenting strategies, preparing assignment and licensing documentation, drafting and negotiating contracts for the evaluation and testing (pre-clinical trials) of the effectiveness of the test kit, working with US counterparts to export the kits, and advising on royalty arrangements with third parties
  • Advising on pharmaceutical patents, including patent protection, freedom to operate, exploitation and multi-jurisdictional patent disputes
  • Drafting and negotiating numerous contracts including licence agreements, JVA and collaboration agreements, NDAs, manufacturing and quality agreements
  • Carrying out a comprehensive review of the IP owned and licensed by a manufacturer of a medicine management system
  • Advising on the branding and labelling of a low-dose preventative medication
  • Advising on advertising clearance and Committee of Advertising Practice standards
  • Making successful representations to OHIM (now the EU Intellectual Property Office) against adverse CTM examination findings
  • Advising on anti-bribery, anti-corruption and compliance issues
  • Undertaking due diligence work in relation to corporate transactions and in-licensing opportunities
  • Advising in relation to the regulatory aspects of clinical trials

PeopleView all

NewsView all